Felicitex Therapeutics is a drug discovery company at the forefront of one of the most promising areas in oncology –dormant (quiescent) cancer cells. We are developing treatments and diagnostic assays to improve the effectiveness and long-term outcomes of treatments for the deadliest and most therapy resistant cancers: hematopoietic, ovarian, pancreatic, colorectal, and lung.